NRIX

Nurix Therapeutics Inc

Add to Watchlist

Advanced Chart

10.460

-0.85(-7.515%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

11.320

Open

11.200

VWAP

10.73

Vol

910.61K

Mkt Cap

799.66M

Low

10.370

Amount

9.77M

EV/EBITDA(TTM)

Total Shares

61.07M

378.86M

EV/OCF(TTM)

P/S(TTM)

10.19

Nurix Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of targeted protein degradation medicines, which is aimed at improving treatment options for patients with cancer and inflammatory diseases. Its wholly owned, clinical-stage pipeline includes three investigational drug candidates: NX-5948, a highly selective degrader of Bruton’s tyrosine kinase (BTK); NX-2127, a dual degrader of BTK and transcription factors IKZF1(Ikaros) and IKZF3 (Aiolos); and NX-1607, an inhibitor of Casitas B-lineage lymphoma proto-oncogene B (CBL-B), an E3 ligase that regulates activation of multiple immune cell types including T cells and NK cells. The Company is also advancing multiple degraders and degrader antibody conjugates (DACs) in its preclinical pipeline. Its partnered drug discovery pipeline consists of preclinical stage degraders of IRAK4 and STAT6, as well as multiple additional programs.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2026Q1

FY2025Q4

FY2025Q3

15.50M

-16%

-0.900

+34.33%

13.36M

+0.6%

-0.895

+19.28%

16.06M

+27.58%

-0.851

+26.97%

Estimates Revision

The market is revising Upward the revenue expectations for Nurix Therapeutics, Inc. (NRIX) for FY2025, with the revenue forecasts being adjusted by 48.46% over the past three months. During the same period, the stock price has changed by 8.45%.

Revenue Estimates for FY2025

Revise Upward

+48.46%

In Past 3 Month

EPS Estimates for FY2025

Revise Downward

-3.82%

In Past 3 Month

Stock Price

Go Up

+8.45%

In Past 3 Month

13 Analyst Rating

175.05% Upside

Wall Street analysts forecast NRIX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for NRIX is 28.77 USD with a low forecast of 16.00 USD and a high forecast of 36.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

11 Buy

2 Hold

0 Sell

Strong Buy

175.05% Upside

Current: 10.460

Low

16.00

Averages

28.77

High

36.00

175.05% Upside

Current: 10.460

Low

16.00

Averages

28.77

High

36.00

Morgan Stanley

Terence Flynn

Equal Weight

downgrade

$17 -> $16

2025-07-15

Reason

Morgan Stanley

Terence Flynn

Price Target

$17 -> $16

2025-07-15

downgrade

Equal Weight

Reason

Morgan Stanley analyst Terence Flynn lowered the firm's price target on Nurix Therapeutics to $16 from $17 and keeps an Equal Weight rating on the shares. Nurix's pipeline is on track with clinical updates expected in 2H25, while bexobrutideg remains the key driver for the stock, with Nurix increasing investment behind the program, the analyst says.

H.C. Wainwright

Buy

downgrade

$36 -> $34

2025-07-14

Reason

H.C. Wainwright

Price Target

$36 -> $34

2025-07-14

downgrade

Buy

Reason

H.C. Wainwright lowered the firm's price target on Nurix Therapeutics to $34 from $36 and keeps a Buy rating on the shares. Nurix last week reported a Q2 net loss of (52c) per share, slightly narrower than the firm's previously estimated net loss of (62c) per share, the analyst tells investors in a research note. The firm is factoring in greater operating expenses moving forward.

UBS

Buy

downgrade

$30 -> $26

2025-07-10

Reason

UBS

Price Target

$30 -> $26

2025-07-10

downgrade

Buy

Reason

UBS lowered the firm's price target on Nurix Therapeutics to $26 from $30 and keeps a Buy rating on the shares. The firm sees asymmetric upside at the current stock price with multiple data catalysts in the next 12 months, the analyst tells investors in a research note.

Oppenheimer

Matthew Biegler

Outperform

maintain

$32 -> $30

2025-07-10

Reason

Oppenheimer

Matthew Biegler

Price Target

$32 -> $30

2025-07-10

maintain

Outperform

Reason

Oppenheimer analyst Matthew Biegler lowered the firm's price target on Nurix Therapeutics to $30 from $32 and keeps an Outperform rating on the shares after the company reported financials. The firm says it is "getting a bit tired of the myopic argument that the CLL market is a zero-sum game." Historically that's never been the case, says Oppenheimer. Ultimately, the firm sees degraders moving up the pecking order into frontline. By Oppenheimer's estimates, NX-5948 is 6-12 months behind BeOne, but has advantages in safety and efficacy that can be exploited.

Wells Fargo

Derek Archila

Buy

Maintains

$32 → $25

2025-04-09

Reason

Wells Fargo

Derek Archila

Price Target

$32 → $25

2025-04-09

Maintains

Buy

Reason

Wells Fargo analyst Derek Archila lowered the firm's price target on Nurix Therapeutics to $25 from $32 and keeps an Overweight rating on the shares. The firm views bexobrutideg as highly de-risked in CLL and thinks regulatory updates and initiation of pivotal trials are modest catalysts in 2025. With shares approaching 52-week lows, it offers an attractive entry point for long-term investors, Wells adds.

Stifel

Stephen Willey

Strong Buy

Maintains

$36 → $35

2025-04-09

Reason

Stifel

Stephen Willey

Price Target

$36 → $35

2025-04-09

Maintains

Strong Buy

Reason

Stifel lowered the firm's price target on Nurix Therapeutics to $35 from $36 and keeps a Buy rating on the shares. The firm continues to view Nurix as "a high-quality company" featuring a lead asset, bexobrutideg, with "a clear path to registration in an established multi-billion-dollar CLL market." The disclosure of incremental bexobrutideg data updates and registrational trial design plans should improve visibility into this path forward, the analyst tells investors.

See All Ratings

Valuation Metrics

The current forward P/E ratio for Nurix Therapeutics Inc (NRIX.O) is -3.17, compared to its 5-year average forward P/E of -6.75. For a more detailed relative valuation and DCF analysis to assess Nurix Therapeutics Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-6.75

Current PE

-3.17

Overvalued PE

-2.40

Undervalued PE

-11.11

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-4.51

Current EV/EBITDA

-1.54

Overvalued EV/EBITDA

-0.11

Undervalued EV/EBITDA

-8.92

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Fair

5Y Average PS

19.68

Current PS

13.73

Overvalued PS

32.45

Undervalued PS

6.90